

Shire – Recall of Kalbitor® (ecallantide)

 On April 12, 2017, the <u>FDA announced</u> a Class II recall of one lot of <u>Kalbitor (ecallantide)</u> injection due to the presence of glass particulate matter.

Product Description	NDC #	Lot # (Expiration date)
Kalbitor (ecallantide) 10 mg/mL single-use vials, packaged as 3 vials per carton	47783-101-01	A1500009 (1/31/2019)

- Kalbitor is indicated for the treatment of acute attacks of hereditary angioedema in patients ≥ 12 years of age.
- Healthcare providers, distributors, wholesalers, and patients should immediately check inventory, quarantine, discontinue distribution, and return all recalled product.
- For questions regarding this recall, contact Shire at 1-800-828-2088.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.